Ustekinumab (Stelara®) is a human IgG1κ monoclonal antibody, directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders. With this function it works immunosuppressive and anti-inflammatory.

PPS has generated considerable experience in the analysis of different originator batches as well as multiple variants of biosimilars of Ustekinumab.

We have established an analytical program according to the ICH Q6B guidance, including the method setup, validation of customer specific methods and release testing.

This package includes different assays for protein quantification and characterizing the protein primary structure and secondary structure, as well as detailed analysis of N-glycosylation and protein modification, including the detailed look for the loss of the C-terminal lysine.


Your contact for Ustekinumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100